PaxMedica, Inc.
We are an early clinical stage biopharmaceutical company focused on the development and testing of our lead program, PAX-101, an intravenous formulation of suramin, in the treatment of autism spectrum disorder (ASD) and the advancement of the clinical understanding of using that agent against other disorders such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID-19 […]
July 3, 2020 Read More